← Patent-cliff monitor small molecule TAFINLAR DABRAFENIB MESYLATE
Loss of exclusivity December 2038 latest FDA-listed patent expiry
Company Novartis → See this company's full patent-cliff portfolio Drug detail Brand name TAFINLAR Active ingredient DABRAFENIB MESYLATE Strength EQ 10MG BASE Dosage form TABLET, FOR SUSPENSION Route ORAL Modality Small molecule FDA approval March 2023 Marketing status RX
Listed patents Patent Expires Type 11504333*PED December 2038 — 11504333 June 2038 product 8703781*PED April 2031 — 8703781 October 2030 substance, product 8415345*PED July 2030 — 7994185*PED July 2030 — 7994185 January 2030 substance, product 8415345 January 2030 substance, product
Regulatory exclusivity Code Expires PED September 2030 ODE-428 March 2030 PED September 2026 NP March 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.